OncoSil Medical announced its first commercial treatments in Greece using the OncoSil device for treating locally advanced pancreatic cancer.
The achievement makes Greece the third European country to conduct commercial treatments with the innovative device, following Italy and Spain.
The treatments are a significant step in OncoSil's commercialisation strategy and a positive signal for the company's long-term sustainability.
The device delivers targeted intratumoral placement of Phosphorous-32 in treating locally advanced unresectable pancreatic cancer.